Summary
A rate on autopsy of up to 30% systemic fungal infections and difficulties in diagnosing systemic mycosis antemortem have led to the empiric use of amphotericin B in patients with hematological malignancies, prolonged fever, and neutropenia. Routine empiric antifungal treatment was initiated in our institution in 1982. Amphotericin B was given to granulocytopenic patients with hematological malignancies with (a) unremitting fever after 48–72 h of antibiotic treatment, (b) recurrent fever during antibiotic treatment, or (c) with newly detected pulmonary infiltrates, sinusitis, skin and retinal lesions suggestive of a fungal infection. With this approach the rate of systemic fungal infections decreased significantly from 10% (27 of 270 patients; 1973–1981) to 4% (6 of 153 patients; 1982–1986,P<0.02). The reduction of systemic fungal infections was most prominent in patients with acute myelogenous leukemia, where its proportion decreased from 16% (16 of 98 patients; 1973–1981) to 4% (2 of 50 patients; 1982–1986,P<0.023). Our data support the hypothesis that the incidence of systemic fungal infections in patients with hematological malignancies and especially in acute myelogenous leukemia can be reduced significantly by empirical treatment with amphotericin B.
Similar content being viewed by others
References
Aisner J, Schimpff SC, Wiernik PH (1977) Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response. Ann Intern Med 86:539–543
Commers JR, Pizzo PA (1983) Empiric antifungal therapy in the management of the febrile-granulocytopenic cancer patient. Pediatr Inf Dis 2:56–60
DeGregorio MW, Lee WMF, Linker CA, Jacobs RA, Ries CA (1982) Fungal infections in patients with acute leukemia. Am J Med 73:543–548
Gold JWM (1984) Opportunistic fungal infections in patients with neoplastic disease. Am J Med 76:458–463
Holleran WM, Wilbur JR, DeGregorio MW (1985) Empiric amphotericin B therapy in patients with acute leukemia. Rev Infect Dis 7:619–624
Klastersky J (1983) Management of infection in granulocytopenic patients. J Antimicrob Chemother 12:102–104
Maksymiuk AW, Thongprasert S, Hopfer R, Luna M, Fainstein V, Bodey GP (1984) Systemic candidiasis in cancer patients. Am J Med 77:20–27
Meunier-Carpentier F (1984) Chemoprophylaxis of fungal infections. Am J Med 76:652–656
Pizzo, PA, Robichaud KJ, Gill FA, Witebsky FG (1982) Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72:101–111
Radaelli F, Cortelezzi A, Zocchi L, Castagnone D, Baldini L, Colombi M, Mozzana R (1986) Diagnosis and treatment of fungal infections in patients with hematologic malignancies. Hematol Oncol 4:129–134
Spearing RL, Pamphilon DH, Prentice AG (1986) Pulmonary aspergillosis in immunosuppressed patients with haematological malignancies. Q J Med 59:611–625
Stahel RA, Vogt P, Schüler G, Rüttner JR, Frick P, Oelz O (1982) Systemic fungal infections in haematological malignancies: a growing problem. J Infection 5:269–275
Stein RS, Kayser J, Flexner JM (1982) Clinical value of empirical amphotericin B in patients with acute myelogenous leukemia. Cancer 50:2247–2251
Stein RS, Greer JP, Ferrin W, Lenox R, Baer MR, Flexner JM (1986) Clinical experience with amphotericin B in acute myelogenous leukemia. South Med J 76:863–870
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zimmermann-Hösli, M.B., Stahel, R.A., Vogt, P. et al. Reduction of systemic fungal infections in patients with hematological malignancies, neutropenia, and prolonged fever by early amphotericin B therapy. Klin Wochenschr 66, 1010–1014 (1988). https://doi.org/10.1007/BF01733443
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01733443